Objective: To assess whether secukinumab treatment in patients with active psoriatic arthritis (PsA) is associated with sustained inhibition of radiographic progression.
Novartis announced that results from the pivotal Phase III FUTURE 1 study for secukinumab in psoriatic arthritis (PsA) were published...
Novartis announced that new one year results from the pivotal Phase III FUTURE 2 study of secukinumab in psoriatic arthritis...
Novartis announced that two pivotal Phase III studies (FUTURE 1 and FUTURE 2) of AIN 457 (secukinumab) in Psoriatic Arthritis...
Novartis announced new results for Cosentyx (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic...
-Novartis announced data showing Cosentyx (secukinumab) shows sustained improvements in the signs and symptoms for active ankylosing spondylitis (AS) at...
Novartis announced that the European Commission (EC) has approved Cosentyx (secukinumab) for the treatment of people living with psoriatic arthritis...
Novartis has announced that the FDA has approved Cosentyx (secukinumab) for the treatment of two new indications - adults with...
Novartis has announced new data from the FUTURE 5 trial showing no radiographic progression (mTSS The trial investigated the effect...
While there are several commercially available treatment options for psoriasis and psoriatic arthritis, there remains a large number of individuals who are refractory to current modalities.